Cdc5 Inhibitors

Cdc5 inhibitors primarily target the polo-like kinase (Plk) family, especially Plk1, due to the functional and structural similarities between Cdc5 and Plk1. The inhibitors listed are primarily Plk1 inhibitors that indirectly affect Cdc5 by disrupting its associated cellular functions. These inhibitors play a critical role in the regulation of the cell cycle, particularly in mitosis and cytokinesis.

The chemical inhibitors interact with the Plk family in various ways. BI 2536, GSK461364, and Volasertib are examples of potent Plk1 inhibitors, which indirectly influence Cdc5 by impeding spindle formation and inducing mitotic arrest. ON01910.Na (Rigosertib) and CYC-116, as multi-kinase inhibitors, target several kinases including Plk1, affecting Cdc5-related pathways. These inhibitors typically induce cell cycle arrest at the G2/M phase, a critical checkpoint in cell division. SBE13, ZK-Thiazolidinone, and TAK-960, among others, exhibit their effect by specifically targeting Plk1, leading to downstream effects on Cdc5 activity. This results in disrupted cell cycle progression, particularly affecting spindle assembly and cytokinesis. HMN-176, an active metabolite of HMN-214, and GW843682X also exhibit Plk1 inhibitory activity, thereby indirectly influencing Cdc5 function.